Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.

@article{Sondak2002AdjuvantIO,
  title={Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.},
  author={Vernon K. Sondak and P Y Liu and Ralph J. Tuthill and Raymond A. Kempf and Joseph M. Unger and Jeffrey A. Sosman and John A. Thompson and Geoffrey Roger Weiss and Bruce G. Redman and James G. Jakowatz and Robert Dirk Noyes and Lawrence E. Flaherty},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 8},
  pages={2058-66}
}
PURPOSE Patients with clinically negative nodes constitute over 85% of new melanoma cases. There is no adjuvant therapy for intermediate-thickness, node-negative melanoma patients. PATIENTS AND METHODS The Southwest Oncology Group conducted a randomized phase III trial of an allogeneic melanoma vaccine for 2 years versus observation in patients with intermediate-thickness (1.5 to 4.0 mm or Clark's level IV if thickness unknown), clinically or pathologically node-negative melanoma (T3N0M0… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Similar Papers

Loading similar papers…